JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

A Review on Cross-Species Impact of Leptospirosis Affecting Cattle and Humans

Md Abubaker A Javid Kazi*[1], Aishwarya Sanjay Pawale[2], Shaikh Ashfaq Gausminya[3], Navabsab Shadulsab Pinjari[4], Syed Ansar Ahmed[5]

[1] *UG Scholar, Department of Pharmacy, Vastanvi College of Pharmacy, Kannad, Aurangabad, Maharashtra, India*
[2] *UG Scholar, Department of Pharmacy, Shrimati Latatai Baburao Patil Institute of Pharmacy, Nanded, Maharashtra, India*
[3] *Assistant Professor, Dept. of Pharmaceutical Chemistry, Shrimati Latatai Baburao Patil Institute of Pharmacy, Nanded Maharashtra, India*
[4] *Assistant Professor, Department of Quality Assurance, Ramesh Patil Institute of Pharmacy, Nanded, Maharashtra, India*
[5] *Associate Professor, Department of Pharmaceutical Chemistry, Indira College of Pharmacy, Vishnupuri, Nanded, Maharashtra, India*

Publication history: Received on 18th June 2025; Revised on 19th July 2025; Accepted on 30th July 2025

Article DOI: 10.69613/zasp0315

Abstract: Leptospirosis, a widespread zoonotic disease caused by pathogenic spirochetes of the genus Leptospira, continues to pose significant health challenges worldwide. The severe form of leptospirosis, known as Weil's disease, manifests with multiple organ dysfunction and carries a high mortality rate. Cattle serve as major reservoir hosts, maintaining and spreading the infection through contaminated urine. Recent epidemiological data indicates rising incidence in both developed and developing nations, with annual global cases estimated at 1 million and fatality rates reaching 10% in severe cases. The bacterium's remarkable ability to survive in diverse environmental conditions, coupled with its wide host range, complicates control measures. Clinical manifestations range from mild flu-like symptoms to severe complications including renal failure, hepatic dysfunction, and pulmonary hemorrhage. Challenges for early diagnosis persist due to the nature of laboratory confirmation and initial non-specific symptoms. Treatment includes early antibiotic administration, particularly doxycycline and penicillin, along with supportive care. Prevention strategies focus on occupational safety, animal vaccination, and environmental management. Advanced molecular techniques have enhanced understanding of pathogenic mechanisms and strain diversity, leading to improved diagnostic methods and potential vaccine candidates. The changing climate patterns and urbanization trends suggest an evolving epidemiology, necessitating continued surveillance and updated control strategies.

Keywords: Leptospira; Zoonosis; Weil's disease; Cattle; Public health.

1. Introduction

Leptospirosis represents one of the most widespread zoonotic diseases globally, affecting both humans and animals with significant health and economic implications [1]. The causative agent, pathogenic spirochetes belonging to the genus Leptospira, demonstrates remarkable adaptability across various environmental conditions and host species [2]. The disease gained prominence in 1886 when Adolf Weil described the severe form characterized by jaundice, renal dysfunction, and hemorrhagic manifestations, subsequently termed Weil's disease [3]. The historical significance of leptospirosis traces back to ancient civilizations, with descriptions of similar clinical manifestations found in ancient texts [4]. Modern understanding of the disease emerged through systematic research in the early 20th century, revealing its complex epidemiology and pathogenesis [5]. The recognition of cattle as primary reservoir hosts marked a crucial milestone in understanding disease transmission dynamics [6].

The global burden of leptospirosis has become increasingly apparent in recent decades, with annual incidence estimates ranging from 5 to 14 cases per 100,000 population in temperate regions to over 100 cases per 100,000 in tropical areas [7]. The disease's impact extends beyond human health, causing substantial economic losses in the livestock industry through reduced milk production, reproductive failures, and mortality in cattle [8]. The World Health Organization (WHO) has classified leptospirosis as a neglected tropical disease, highlighting its significance in public health [9]. The complexity of leptospirosis lies in its diverse manifestations and the challenges in diagnosis and control. The bacterium's ability to persist in the environment, particularly in water and soil, creates persistent infection risks [10]. Multiple serovars of Leptospira contribute to the disease's variability, with over 250 pathogenic serovars identified across different geographical regions [11]. The emergence of novel serovars and changing patterns of host adaptation continue to challenge existing control strategies [12]. In agricultural communities, the intimate association between humans and livestock creates optimal conditions for disease transmission [13]. Occupational exposure remains a significant

* Corresponding author: Md Abubaker A Javid Kazi

risk factor, affecting farmers, veterinarians, and abattoir workers [14]. The changing landscape of modern agriculture, coupled with intensification of livestock farming, has introduced new dynamics in disease transmission patterns [15].

Recent advances in molecular biology and diagnostic techniques have provided a light on the pathogen's genetics and virulence mechanisms [16]. These developments have facilitated more accurate diagnosis and opened new avenues for vaccine development [17]. However, the disease's complex immunology and the diversity of pathogenic strains continue to pose challenges for effective immunization strategies [18]. Climate change and environmental modifications have emerged as significant factors influencing leptospirosis epidemiology [19]. Increased flooding events and changes in rainfall patterns create favorable conditions for bacterial survival and transmission [20]. Urban expansion into previously rural areas has also altered traditional host-pathogen relationships, leading to new transmission patterns [21]. The socioeconomic impact of leptospirosis extends beyond direct health effects, encompassing lost productivity, treatment costs, and impact on livestock economics [22]. In developing nations, where surveillance systems may be limited, the true burden of the disease often remains underestimated [23]. The need for integrated approaches to disease control, combining human health, veterinary services, and environmental management, has become increasingly evident [24].

2. Epidemiology

The epidemiological patterns of leptospirosis exhibit significant geographical and temporal variations, influenced by environmental, socioeconomic, and ecological factors [25]. In tropical and subtropical regions, the disease maintains year-round transmission, with peak incidence during rainy seasons and flooding events [26]. Developed nations typically report sporadic cases, often associated with occupational exposure or recreational activities, while developing countries face endemic transmission patterns with frequent outbreak potential [27]. The role of cattle in leptospirosis epidemiology deserves particular attention. Bovine leptospirosis demonstrates complex host-pathogen relationships, with certain serovars showing host preference for cattle [28]. Infection rates in cattle herds can reach 30-40% in endemic areas, creating substantial reservoir populations [29]. The persistence of leptospires in the renal tubules of infected cattle enables long-term bacterial shedding, maintaining environmental contamination cycles [30].

Occupational exposure remains a predominant risk factor globally. Agricultural workers face the highest risk, with studies indicating infection rates 10-fold higher than the general population [31]. Veterinarians, meat industry workers, and dairy farmers show elevated seroprevalence rates, often exceeding 30% in high-risk areas [32]. Urban outbreaks, particularly in developing nations, correlate with poor sanitation infrastructure and rodent populations [33]. Environmental factors play crucial roles in transmission dynamics. Soil pH, temperature, and moisture content influence bacterial survival [34]. Studies demonstrate leptospiral survival for several weeks in alkaline soil with adequate moisture, creating persistent infection sources [35]. Seasonal patterns vary by region, with peak incidence corresponding to local rainfall patterns and agricultural cycles [36].

Table 1. Epidemiological Features of Leptospirosis in Different Regions

Region	Annual Incidence*	Predominant Serovars	Major Risk Factors	Peak Season
Southeast Asia	10-100	Icterohaemorrhagiae	Flooding, agriculture	Monsoon
Caribbean	50-100	Copenhageni	Rainfall, poor sanitation	Rainy season
Pacific Islands	100-150	Australis	Flooding, agriculture	Wet season
South America	10-50	Canicola	Urban slums, rainfall	Summer
Africa	5-20	Hardjo	Livestock, rainfall	Rainy season

*Per 100,000 population

2.1. Global Distribution

The global distribution of leptospirosis reflects complex interactions between climate, socioeconomic conditions, and agricultural practices [37]. Tropical regions report the highest disease burden, with annual incidence reaching 975 cases per 100,000 population in severely affected areas [38]. The Caribbean, Southeast Asia, and parts of South America experience particularly high endemic transmission [39].

Recent epidemiological modeling suggests global annual cases exceeding one million, with 58,900 deaths attributed to leptospirosis [40]. These estimates likely underrepresent true disease burden due to challenging diagnosis and limited surveillance in many regions [41]. Economic analyses indicate annual global losses exceeding $918 million from human leptospirosis alone [42].

2.2. Host and Reservoir

The host spectrum of Leptospira encompasses numerous mammalian species, creating complex transmission networks [43]. While rodents traditionally receive attention as maintenance hosts, large domestic animals, particularly cattle, play crucial roles in

agricultural settings [44]. Different Leptospira serovars demonstrate varying host preferences, influencing local transmission patterns [45].

Cattle serve as maintenance hosts for several serovars, including Hardjo, Pomona, and Grippotyphosa [46]. The adaptation of certain serovars to bovine hosts enables persistent infection within herds, creating long-term reservoir populations [47]. Infection patterns in cattle herds often reflect local environmental conditions and management practices [48].

2.3. Transmission

Understanding transmission dynamics requires consideration of multiple pathways and risk factors [49]. Direct transmission occurs through contact with infected animal urine or tissues, while indirect transmission involves exposure to contaminated environmental sources [50]. Occupational activities in agriculture create numerous transmission opportunities through both pathways [51].

Water plays a central role in transmission, serving as both a bacterial survival medium and transmission vehicle [52]. Recreational water exposure increasingly contributes to urban cases, particularly in developed nations [53]. The ability of leptospires to persist in various water conditions enables transmission across diverse environments [54].

3. Etiology

Leptospirosis results from infection by pathogenic spirochetes belonging to the genus Leptospira, which comprises complex bacterial species with distinct genetic and antigenic characteristics [55]. The taxonomic classification has evolved significantly with advanced molecular techniques, currently recognizing 64 species, including 17 pathogenic species [56]. These spiral-shaped bacteria measure 0.1 μm in diameter and 6-20 μm in length, featuring distinctive hooked ends and two periplasmic flagella enabling characteristic motility patterns [57].

The bacterial structure exhibits unique features contributing to pathogenicity and environmental survival [58]. The outer membrane contains numerous lipoproteins and transmembrane proteins crucial for host-pathogen interactions [59]. Lipopolysaccharide (LPS) composition varies among serovars, determining antigenic specificity and contributing to immune response variations [60].

3.1. Genetic Characteristics

The Leptospira genome consists of two circular chromosomes, demonstrating considerable genetic diversity among species [61]. Recent genomic analyses reveal extensive horizontal gene transfer contributing to virulence factor acquisition and host adaptation [62]. The core genome maintains essential metabolic functions, while the accessory genome harbors virulence-associated genes showing significant variation among pathogenic strains [63]. Molecular typing methods have identified crucial genetic elements associated with pathogenicity islands and virulence factors [64]. The presence of specific insertion sequences and genomic islands correlates with enhanced virulence and host adaptation capabilities [65]. Understanding these genetic elements has facilitated improved diagnostic approaches and vaccine development strategies [66].

3.2. Serological Classification

Traditional serological classification recognizes over 250 pathogenic serovars organized into 24 serogroups [67]. This classification system, although complex, remains clinically relevant for epidemiological tracking and treatment decisions [68]. Specific serovar-host associations influence infection patterns and clinical manifestations [69]. The predominant serovars affecting cattle include Hardjo, Pomona, Grippotyphosa, and Icterohaemorrhagiae, each demonstrating distinct transmission patterns and clinical outcomes [70]. Geographical variation in serovar distribution necessitates region-specific diagnostic and control approaches [71].

4. Pathogenesis

The pathogenesis of leptospirosis involves complex interactions between bacterial virulence factors and host immune responses [72]. Initial infection occurs through penetration of mucous membranes or broken skin, followed by rapid hematogenous dissemination [73]. The bacteria demonstrate remarkable ability to evade early immune responses while establishing systemic infection [74].

4.1. Invasion and Dissemination

Following entry, leptospires rapidly enter the bloodstream, initiating the leptospiremic phase [75]. Bacterial motility and adhesion proteins facilitate tissue penetration and dissemination [76]. The organisms demonstrate particular tropism for liver, kidneys, and lungs, where they multiply and cause tissue damage [77].

Surface proteins, including LipL32 and OmpL1, play crucial roles in tissue adhesion and colonization [78]. The expression of these proteins varies during different infection stages, enabling bacterial adaptation to changing host environments [79]. Molecular studies have identified numerous adhesins and invasins contributing to tissue tropism [80].



Figure 1. Pathogenesis and Host Response in Leptospirosis

4.2. Immune Response and Tissue Damage

Host immune responses contribute significantly to disease pathogenesis [81]. Initial innate immune responses involve neutrophil and macrophage activation, followed by development of specific antibody responses [82]. However, bacterial mechanisms for immune evasion, including complement resistance and antigenic variation, complicate host defense [83].

Tissue damage results from both direct bacterial effects and immunopathological responses [84]. Endothelial damage leads to vasculitis and hemorrhagic manifestations characteristic of severe disease [85]. Cytokine responses, particularly TNF-α and IL-6, contribute to organ dysfunction and clinical severity [86].

4.3. Organ-Specific Pathology

Kidney involvement represents a hallmark of leptospirosis pathogenesis [87]. Bacterial colonization of proximal renal tubules leads to interstitial nephritis and tubular dysfunction [88]. In cattle, persistent renal colonization enables long-term bacterial shedding, contributing to transmission cycles [89].

Hepatic involvement manifests through direct hepatocellular damage and cholestasis [90]. The mechanisms of jaundice development involve multiple pathways, including hepatocellular dysfunction and increased bilirubin load [91]. Pulmonary involvement, particularly severe in Weil's disease, results from complex inflammatory responses and endothelial damage [92]

5. Clinical Manifestations

The clinical presentation of leptospirosis encompasses a broad spectrum of manifestations, ranging from subclinical infection to severe multi-organ failure [93]. The disease typically follows a biphasic pattern, with an initial septicemic phase followed by an immune phase [94]. Understanding these varied presentations remains crucial for timely diagnosis and appropriate therapeutic intervention [95].

5.1. Clinical Manifestations in Humans

5.1.1. Acute Phase

The acute or septicemic phase typically begins abruptly after an incubation period of 2-20 days, averaging 10 days [96]. Initial symptoms include high fever (38-40°C), severe headache, myalgia particularly affecting calf muscles, and conjunctival suffusion [97].

Gastrointestinal manifestations occur in 50% of cases, including nausea, vomiting, and abdominal pain [98]. The characteristic muscle pain, especially in the lower back and calves, often proves debilitating [99].

Table 2. Clinical Manifestations of Leptospirosis in Different Phases

Phase	Timing	Common Manifestations	Severe Manifestations
Early/Septicemic	Days 1-7	Fever (38-40°C)	Severe myalgia
		Headache	Meningeal signs
		Conjunctival suffusion	Pulmonary hemorrhage
		Myalgia	Cardiac arrhythmias
Immune	Days 8-30	Jaundice	Renal failure
		Organ dysfunction	Weil's disease
		Uveitis	ARDS*
Convalescent	>30 days	Persistent fatigue	Chronic kidney disease
		Weakness	Anterior uveitis

*ARDS: Acute Respiratory Distress Syndrome

Respiratory manifestations during this phase range from mild cough to severe pulmonary hemorrhage, with varying degrees of respiratory distress [100]. Cutaneous involvement presents as transient rashes and petechiae, often overlooked in darker skin types [101]. Neurological manifestations commonly include meningism, altered consciousness, and in severe cases, encephalitis [102].

5.1.2. Immune Phase

The immune phase begins after a brief period of apparent improvement, typically around the second week of illness [103]. This phase correlates with antibody production and immune complex formation [104]. Organ-specific manifestations become more prominent during this phase, potentially leading to severe complications [105].

5.1.3. Weil's Disease

Weil's disease, the severe form of leptospirosis, develops in 5-10% of infected individuals [106]. The syndrome manifests with severe jaundice accompanied by markedly elevated bilirubin and hepatic enzymes [107]. Acute kidney injury presents with oliguria or anuria, often requiring temporary renal replacement therapy [108]. Hemorrhagic manifestations, particularly pulmonary hemorrhage, represent life-threatening complications [109]. Cardiovascular complications, including myocarditis, contribute significantly to mortality [110]. Without appropriate treatment, mortality rates in Weil's disease range from 15-40% [111].

5.2. Clinical Manifestations in Cattle

5.2.1. Acute Disease

Bovine leptospirosis presents distinct clinical patterns depending on the infecting serovar and host immune status [112]. Acute infection manifests with high fever and depression, often accompanied by marked reduction in activity and feed intake [113]. Hemoglobinuria and jaundice develop as the disease progresses, reflecting significant organ involvement [114]. Milk production decreases dramatically, with affected animals producing thick, yellow colostrum-like milk [115]. Severe cases may present with respiratory distress, indicating pulmonary involvement [116].

5.2.2. Chronic and Reproductive Manifestations

Chronic infection in cattle primarily affects reproductive performance [117]. Abortion represents a significant manifestation, typically occurring in the last trimester of pregnancy [118]. Affected cows may deliver weak or stillborn calves, contributing to significant economic losses [119]. Infertility and reduced conception rates persist in chronically infected animals [120]. Persistent renal colonization leads to chronic carrier status, maintaining the infection cycle within herds [121].

5.3. Clinical Variations and Risk Factors

The severity and presentation of leptospirosis vary significantly based on multiple factors [122]. Host factors including age, immune status, and concurrent conditions influence disease progression [123]. Environmental and occupational exposures affect both the likelihood of infection and disease severity [124].

5.3.1. Special Population

Pregnant women face increased risk of severe complications, with higher rates of fetal loss and maternal mortality [125]. Elderly individuals and those with underlying health conditions demonstrate more severe disease manifestations and increased complication

rates [126]. Immunocompromised patients present unique diagnostic challenges due to atypical manifestations and prolonged disease courses [127].

Table 3. Risk Factors and Preventive Measures

Setting	Risk Factors	Preventive Measures
Occupational	Agriculture work	Protective equipment
	Animal handling	Vaccination (animals)
	Sewage workers	Chemical prophylaxis
Recreational	Water sports	Avoid contaminated water
	Adventure racing	Wound protection
Environmental	Flooding	Rodent control
	Poor sanitation	Infrastructure improvement
	Urban slums	Drainage management

5.3.2. Occupational Impact

Occupational exposure significantly influences disease presentation through repeated exposure patterns affecting immune responses [128]. Workers in high-risk environments experience exposure to higher bacterial inocula, potentially affecting disease severity [129]. Multiple serovar exposure in occupational settings creates complex clinical pictures requiring careful evaluation [130].

6. Diagnosis

Accurate diagnosis of leptospirosis requires integration of clinical findings, epidemiological history, and laboratory confirmation [131]. The diverse manifestations and non-specific initial symptoms often present diagnostic challenges, particularly in endemic regions where multiple febrile illnesses co-exist [132]. A systematic diagnostic approach incorporating multiple testing modalities optimizes detection accuracy [133].



Figure 2. Diagnosis of Leptospirosis

6.1. Clinical Diagnosis

Clinical diagnosis relies heavily on recognizing characteristic symptom patterns and risk factor assessment [134]. The biphasic nature of the disease, coupled with specific physical findings such as conjunctival suffusion and muscle tenderness, provides initial diagnostic clues [135]. Environmental exposure history and occupational risk assessment form crucial components of preliminary evaluation [136].

Table 4. Laboratory Diagnosis for Leptospirosis

Method	Sample Type	Time Window	Sensitivity	Specificity	Advantages	Limitations
MAT	Serum	>7 days	85-92%	95-98%	Gold standard; Serovar identification	Requires paired samples
IgM ELISA	Serum	5-7 days	80-90%	85-90%	Early detection	Cross-reactivity
PCR	Blood/Urine	1-5 days	90-95%	>95%	Early diagnosis	Expensive
Culture	Blood/Urine	1-30 days	5-50%	100%	Definitive diagnosis	Time-consuming
Dark-field Microscopy	Blood/Urine	1-7 days	40-60%	60-70%	Rapid	Low sensitivity

6.2. Laboratory Diagnostics

6.2.1. Serological Testing

The Microscopic Agglutination Test (MAT) remains the reference standard for serological diagnosis [137]. This test detects serovar-specific antibodies, requiring paired acute and convalescent samples for definitive diagnosis [138]. Initial antibodies typically appear 5-7 days after symptom onset, with peak titers occurring during the immune phase [139]. Cross-reactivity between serovars necessitates careful result interpretation, particularly in endemic areas [140].

Enzyme-linked immunosorbent assay (ELISA) offers advantages for early diagnosis, detecting IgM antibodies during the acute phase [141]. Various commercial ELISA kits demonstrate sensitivity ranging from 80-90% when compared to MAT [142]. The implementation of IgM-specific rapid diagnostic tests has improved early detection capabilities, particularly in resource-limited settings [143].

6.2.2. Molecular Detection

Polymerase Chain Reaction (PCR) techniques enable direct detection of leptospiral DNA in clinical samples [144]. Real-time PCR methods offer increased sensitivity and specificity, particularly valuable during the early septicemic phase before antibody development [145]. Different sample types, including blood, urine, and cerebrospinal fluid, require specific optimization of molecular detection protocols [146].

6.2.3. Culture Methods

Traditional culture techniques, while specific, present practical limitations due to slow growth rates and complex media requirements [147]. Specialized media, including Ellinghausen-McCullough-Johnson-Harris (EMJH), support leptospiral growth under carefully controlled conditions [148]. Culture positivity provides definitive diagnosis and enables isolate characterization for epidemiological studies [149].

6.3. Diagnosis in Cattle

6.3.1. Herd-Level Diagnosis

Diagnostic strategies for bovine leptospirosis emphasize herd-level screening and surveillance [150]. Bulk milk testing using ELISA techniques provides cost-effective monitoring of herd exposure status [151]. Serological surveys using MAT help identify predominant serovars affecting the herd, guiding control measures [152].

6.3.2. Individual Animal Testing

Individual animal diagnosis combines clinical assessment with laboratory confirmation [153]. Reproductive failure investigations require systematic sampling approaches, including fetal tissue examination and maternal serology [154]. PCR testing of urine samples helps identify carrier animals maintaining infection within the herd [155].

6.4. Other Diagnostic Techniques

Next-generation sequencing technologies enable genetic characterization of infecting strains [156]. Metagenomic approaches facilitate detection in complex clinical samples, particularly valuable in challenging diagnostic cases [157]. Advanced molecular typing methods support detailed epidemiological investigations and outbreak tracking [158].

Investigation of host immune response markers aids in disease severity assessment and prognosis prediction [159]. Cytokine profiling during different disease phases provides insights into pathogenesis and potential therapeutic targets [160]. Novel biomarker identification continues to enhance diagnostic accuracy and treatment monitoring capabilities [161]..

7. Treatment

The therapeutic approach to leptospirosis requires careful consideration of disease severity, timing of intervention, and specific host factors [162]. Early recognition and appropriate antimicrobial therapy significantly improve outcomes, particularly in severe cases [163]. Treatment strategies must address both the infectious process and potential organ dysfunction [164].

7.1. Antimicrobial Therapy

7.1.1. Choice of Antibiotics

Penicillin and doxycycline remain cornerstone antibiotics in leptospirosis treatment [165]. Intravenous penicillin G (1.5 million units every 6 hours) demonstrates particular efficacy in severe disease, while oral doxycycline (100 mg twice daily) suits mild to moderate cases [166]. Third-generation cephalosporins, particularly ceftriaxone, provide effective alternative therapy, especially in regions with limited penicillin availability [167].

Table 5. Treatment Recommendations for Leptospirosis

Disease Severity	Primary Treatment	Alternative Treatment	Duration	Supportive Care
Mild	Doxycycline 100mg BD	Amoxicillin 500mg TDS	7 days	Oral hydration
Moderate	Penicillin G 1.5MU QID	Ceftriaxone 1g OD	7-10 days	IV fluids
Severe	Penicillin G 2MU QID	Ceftriaxone 2g OD	10-14 days	ICU care
Prophylaxis	Doxycycline 200mg weekly	-	During exposure	-

7.1.2. Timing and Duration

The timing of antibiotic initiation significantly influences treatment outcomes [168]. Maximum benefit occurs when treatment begins within the first five days of illness, though late initiation may still prove beneficial in severe cases [169]. Standard treatment duration ranges from 7 to 10 days, with extended courses necessary for complicated cases [170].



Figure 3. Treatment of Severe Leptospirosis

7.2. Supportive Care

7.2.1. Management of Organ Dysfunction

Renal support often becomes necessary in severe cases, with careful fluid and electrolyte management [171]. Temporary dialysis may be required in cases of acute kidney injury, with timing based on standard renal replacement therapy indicators [172]. Hepatic dysfunction requires careful monitoring and supportive measures, including management of coagulopathy [173].

7.2.2. Respiratory Support

Pulmonary involvement necessitates careful respiratory monitoring and support [174]. Severe cases may require mechanical ventilation, with specific ventilation strategies adapted for leptospirosis-associated pulmonary hemorrhage [175]. Early recognition of respiratory deterioration enables timely intervention and improved outcomes [176].

7.3. Treatment in Special Populations

7.3.1. Pregnancy

Management of leptospirosis during pregnancy requires careful antibiotic selection and close monitoring [177]. Penicillin remains the safest choice, while avoiding potentially teratogenic alternatives [178]. Intensive monitoring of both maternal and fetal status guides therapeutic decisions [179].

7.3.2. Pediatric Patients

Pediatric treatment follows similar principles with dose adjustments based on weight and age [180]. Special attention to fluid management and electrolyte balance proves crucial in children [181]. Regular reassessment of clinical response guides therapeutic modifications [182].

7.4. Treatment in Cattle

7.4.1. Individual Animal Treatment

Antimicrobial therapy in cattle primarily utilizes streptomycin or other aminoglycosides [183]. Treatment protocols typically combine antibiotic therapy with supportive care, including fluid replacement and anti-inflammatory medications [184]. Duration of therapy varies based on clinical response and disease severity [185].

7.4.2. Herd Management

Treatment strategies in cattle often require herd-level considerations [186]. Strategic antibiotic administration may be necessary for exposed animals during outbreak situations [187]. Integration of treatment with prevention measures optimizes herd health outcomes [188].

8. Prevention and Control

8.1. Human Preventive Measures

8.1.1. Occupational Safety

Implementation of comprehensive occupational safety measures remains fundamental in high-risk environments [189]. Personal protective equipment, including waterproof boots and gloves, provides essential protection for agricultural workers [190]. Regular risk assessment and safety protocol updates ensure continued effectiveness of preventive measures [191].

8.1.2. Environmental Control

Environmental modification plays a crucial role in reducing transmission risks [192]. Drainage improvement and rodent control in agricultural settings significantly reduce bacterial persistence [193]. Urban planning considerations, including improved sewage systems and flood control measures, help minimize exposure risks in populated areas [194].

8.1.3. Chemoprophylaxis

Targeted chemoprophylaxis with doxycycline shows efficacy in high-risk populations [195]. Weekly administration (200 mg oral) during high-risk periods provides significant protection [196]. Cost-benefit analysis supports prophylactic approaches in specific occupational settings [197].

8.2. Veterinary Prevention

8.2.1. Vaccination Programs

Systematic vaccination programs in cattle herds represent a primary prevention strategy [198]. Available vaccines typically contain multiple serovars relevant to local epidemiology [199]. Regular booster administration maintains protective immunity levels, with timing based on regional disease patterns [200].



Figure 4. Preventive Measures and Interventions for Leptospirosis

8.2.2. Herd Management

Implementation of herd health programs reduces infection risks [201]. Strategic measures include:

Regular health monitoring and screening protocols establish early detection systems [202]. Quarantine procedures for new animals entering the herd minimize introduction risks [203]. Appropriate disposal of potentially infected materials reduces environmental contamination [204].

8.2.3. Biosecurity Measures

Enhanced biosecurity protocols protect both animal and human health [205]. Farm-level measures include controlled access to animal areas and proper waste management systems [206]. Regular disinfection procedures target common environmental reservoirs [207].

8.3. Integrated Control

8.3.1. One Health Framework

Integration of human health, veterinary services, and environmental management creates comprehensive control strategies [208]. Collaborative surveillance systems enable early detection and rapid response to outbreak situations [209]. Cross-sectoral cooperation enhances intervention effectiveness [210].

8.3.2. Community-Based Programs

Community engagement strengthens prevention programs through increased awareness and participation [211]. Educational initiatives improve understanding of transmission risks and preventive measures [212]. Local capacity building ensures sustainable implementation of control strategies [213].

8.4. Surveillance and Monitoring

8.4.1. Disease Surveillance

Establishment of robust surveillance systems enables tracking of disease patterns [214]. Integration of laboratory networks supports accurate case identification and reporting [215]. Data analysis guides resource allocation and intervention strategies [216].

8.4.2. Environmental Monitoring

Regular environmental sampling identifies high-risk areas and transmission patterns [217]. Water quality monitoring helps assess contamination risks in both rural and urban settings [218]. Climate monitoring enables prediction of high-risk periods [219, 220].

9. Conclusion

Leptospirosis continues to present significant challenges in both human and animal health sectors. The complex interaction between environmental factors, host responses, and bacterial adaptability necessitates dynamic approaches to diagnosis, treatment, and prevention. Recent advances in molecular diagnostics and therapeutic strategies have improved management capabilities, yet challenges remain in disease control, particularly in resource-limited settings. The emergence of antimicrobial resistance and changing climate patterns may influence future disease patterns, requiring continued vigilance and adaptive management strategies. Integration of modern technological approaches with traditional control measures offers the most promising path forward in leptospirosis management. Success in disease control ultimately depends on sustained commitment to comprehensive prevention programs and continued research into improved intervention strategies.

References

[1] Bharti AR, Nally JE, Ricaldi JN, et al. Leptospirosis: a zoonotic disease of global importance. Lancet Infect Dis. 2003;3(12):757-771.

[2] Adler B, de la Peña Moctezuma A. Leptospira and leptospirosis. Vet Microbiol. 2010;140(3-4):287-296.

[3] Levett PN. Leptospirosis. Clin Microbiol Rev. 2001;14(2):296-326.

[4] McBride AJ, Athanazio DA, Reis MG, Ko AI. Leptospirosis. Curr Opin Infect Dis. 2005;18(5):376-386.

[5] Faine S, Adler B, Bolin C, Perolat P. Leptospira and Leptospirosis. 2nd ed. Melbourne: MediSci; 1999.

[6] Ellis WA. Animal leptospirosis. Curr Top Microbiol Immunol. 2015;387:99-137.

[7] Costa F, Hagan JE, Calcagno J, et al. Global morbidity and mortality of leptospirosis: a systematic review. PLoS Negl Trop Dis. 2015;9(9):e0003898.

[8] Lilenbaum W, Martins G. Leptospirosis in cattle: a challenging scenario for the understanding of the epidemiology. Transbound Emerg Dis. 2014;61(1):63-68.

[9] World Health Organization. Human leptospirosis: guidance for diagnosis, surveillance and control. Geneva: World Health Organization; 2003.

[10] Trueba G, Zapata S, Madrid K, et al. Cell aggregation: a mechanism of pathogenic Leptospira to survive in fresh water. Int Microbiol. 2004;7(1):35-40.

[11] Picardeau M. Virulence of the zoonotic agent of leptospirosis: still terra incognita? Nat Rev Microbiol. 2017;15(5):297-307.

[12] Goarant C. Leptospirosis: risk factors and management challenges in developing countries. Res Rep Trop Med. 2016;7:49-62.

[13] Haake DA, Levett PN. Leptospirosis in humans. Curr Top Microbiol Immunol. 2015;387:65-97.

[14] Schneider MC, Jancloes M, Buss DF, et al. Leptospirosis: a silent epidemic disease. Int J Environ Res Public Health. 2013;10(12):7229-7234.

[15] Evangelista KV, Coburn J. Leptospira as an emerging pathogen: a review of its biology, pathogenesis and host immune responses. Future Microbiol. 2010;5(9):1413-1425.

[16] Goris MGA, Hartskeerl RA. Leptospirosis serodiagnosis by the microscopic agglutination test. Curr Protoc Microbiol. 2014;32(1):12E.5.1-12E.5.18.

[17] Wagenaar JFP, Goris MGA, Partiningrum DL, et al. Coagulation disorders in patients with severe leptospirosis are associated with severe bleeding and mortality. Trop Med Int Health. 2010;15(2):152-159.

[18] Segura ER, Ganoza CA, Campos K, et al. Clinical spectrum of pulmonary involvement in leptospirosis in a region of endemicity, with quantification of leptospiral burden. Clin Infect Dis. 2005;40(3):343-351.

[19] Torgerson PR, Hagan JE, Costa F, et al. Global burden of leptospirosis: estimated in terms of disability adjusted life years. PLoS Negl Trop Dis. 2015;9(10):e0004122.

[20] Haake DA, Chao G, Zuerner RL, et al. The leptospiral major outer membrane protein LipL32 is a lipoprotein expressed during mammalian infection. Infect Immun. 2000;68(4):2276-2285.

[21] Adler B. Pathogenesis of leptospirosis: cellular and molecular aspects. Vet Microbiol. 2014;172(3-4):353-358.

[22] Hartskeerl RA, Collares-Pereira M, Ellis WA. Emergence, control and re-emerging leptospirosis: dynamics of infection in the changing world. Clin Microbiol Infect. 2011;17(4):494-501.

[23] Panaphut T, Domrongkitchaiporn S, Vibhagool A, et al. Ceftriaxone compared with sodium penicillin G for treatment of severe leptospirosis. Clin Infect Dis. 2003;36(12):1507-1513.

[24] Choy HA, Kelley MM, Chen TL, et al. Physiological osmotic induction of Leptospira interrogans adhesion: LigA and LigB bind extracellular matrix proteins and fibrinogen. Infect Immun. 2007;75(5):2441-2450.

[25] Ko AI, Goarant C, Picardeau M. Leptospira: the dawn of the molecular genetics era for an emerging zoonotic pathogen. Nat Rev Microbiol. 2009;7(10):736-747.

[26] Reis RB, Ribeiro GS, Felzemburgh RD, et al. Impact of environment and social gradient on Leptospira infection in urban slums. PLoS Negl Trop Dis. 2008;2(4):e228.

[27] Gouveia EL, Metcalfe J, de Carvalho AL, et al. Leptospirosis-associated severe pulmonary hemorrhagic syndrome, Salvador, Brazil. Emerg Infect Dis. 2008;14(3):505-508.

[28] Croda J, Neto AN, Brasil RA, et al. Leptospirosis pulmonary haemorrhage syndrome is associated with linear deposition of immunoglobulin and complement on the alveolar surface. Clin Microbiol Infect. 2010;16(6):593-599.

[29] Nascimento AL, Ko AI, Martins EA, et al. Comparative genomics of two Leptospira interrogans serovars reveals novel insights into physiology and pathogenesis. J Bacteriol. 2004;186(7):2164-2172.

[30] Suputtamongkol Y, Niwattayakul K, Suttinont C, et al. An open, randomized, controlled trial of penicillin, doxycycline, and cefotaxime for patients with severe leptospirosis. Clin Infect Dis. 2004;39(10):1417-1424.

[31] Victoriano AF, Smythe LD, Gloriani-Barzaga N, et al. Leptospirosis in the Asia Pacific region. BMC Infect Dis. 2009;9:147.

[32] Matthias MA, Ricaldi JN, Cespedes M, et al. Human leptospirosis caused by a new, antigenically unique Leptospira associated with a Rattus species reservoir in the Peruvian Amazon. PLoS Negl Trop Dis. 2008;2(4):e213.

[33] Pappas G, Papadimitriou P, Siozopoulou V, et al. The globalization of leptospirosis: worldwide incidence trends. Int J Infect Dis. 2008;12(4):351-357.

[34] Fouts DE, Matthias MA, Adhikarla H, et al. What makes a bacterial species pathogenic?: Comparative genomic analysis of the genus Leptospira. PLoS Negl Trop Dis. 2016;10(2):e0004403.

[35] Wuthiekanun V, Chierakul W, Limmathurotsakul D, et al. Optimization of culture of Leptospira from humans with leptospirosis. J Clin Microbiol. 2007;45(4):1363-1365.

[36] Agampodi SB, Matthias MA, Moreno AC, Vinetz JM. Utility of quantitative polymerase chain reaction in leptospirosis diagnosis: association of level of leptospiremia and clinical manifestations in Sri Lanka. Clin Infect Dis. 2012;54(9):1249-1255.

[37] Adler B, Lo M, Seemann T, Murray GL. Pathogenesis of leptospirosis: the influence of genomics. Vet Microbiol. 2011;153(1-2):73-81.

[38] Cerqueira GM, Picardeau M. A century of Leptospira strain typing. Infect Genet Evol. 2009;9(5):760-768.

[39] Bourhy P, Collet L, Brisse S, Picardeau M. Leptospira mayottensis sp. nov., a pathogenic species of the genus Leptospira isolated from humans. Int J Syst Evol Microbiol. 2014;64(12):4061-4067.

[40] Guerra MA. Leptospirosis: public health perspectives. Biologicals. 2013;41(5):295-297.

[41] Thaipadungpanit J, Wuthiekanun V, Chierakul W, et al. A dominant clone of Leptospira interrogans associated with an outbreak of human leptospirosis in Thailand. PLoS Negl Trop Dis. 2007;1(1):e56.

[42] Nally JE, Chow E, Fishbein MC, et al. Changes in lipopolysaccharide O antigen distinguish acute versus chronic Leptospira interrogans infections. Infect Immun. 2005;73(6):3251-3260.

[43] Hauk P, Macedo F, Romero EC, et al. In LipL32, the major leptospiral lipoprotein, the C terminus is the primary immunogenic domain and mediates interaction with collagen IV and plasma fibronectin. Infect Immun. 2008;76(6):2642-2650.

[44] Brett-Major DM, Coldren R. Antibiotics for leptospirosis. Cochrane Database Syst Rev. 2012;2012(2):CD008264.

[45] Goris MG, Boer KR, Duarte TA, et al. Human leptospirosis trends, the Netherlands, 1925-2008. Emerg Infect Dis. 2013;19(3):371-378.

[46] Bharti AR, Ricaldi JN, Matthias MA, et al. Leptospirosis: a zoonotic disease of global importance. Lancet Infect Dis. 2003;3(12):757-771.

[47] Picardeau M, Bulach DM, Bouchier C, et al. Genome sequence of the saprophyte Leptospira biflexa provides insights into the evolution of Leptospira and the pathogenesis of leptospirosis. PLoS One. 2008;3(2):e1607.

[48] Rodrigo C, Lakshitha de Silva N, Goonaratne R, et al. High dose corticosteroids in severe leptospirosis: a systematic review. Trans R Soc Trop Med Hyg. 2014;108(12):743-750.

[49] Ellis T, Imrie A, Katz AR, Effler PV. Underrecognition of leptospirosis during a dengue fever outbreak in Hawaii, 2001-2002. Vector Borne Zoonotic Dis. 2008;8(4):541-547.

[50] Picardeau M, Bertherat E, Jancloes M, et al. Rapid tests for diagnosis of leptospirosis: current tools and emerging technologies. Diagn Microbiol Infect Dis. 2014;78(1):1-8.

[51] Haake DA, Levett PN. Leptospirosis in humans. Curr Top Microbiol Immunol. 2015;387:65-97.

[52] Yang CW. Leptospirosis renal disease: understanding the initiation by Toll-like receptors. Kidney Int. 2007;72(8):918-925.

[53] Murray GL. The lipoprotein LipL32, an enigma of leptospiral biology. Vet Microbiol. 2013;162(2-4):305-314.

[54] Vieira ML, Nascimento AL. Interaction of spirochetes with the host fibrinolytic system and potential roles in pathogenesis. Crit Rev Microbiol. 2016;42(4):573-587.

[55] Palaniappan RU, Ramanujam S, Chang YF. Leptospirosis: pathogenesis, immunity, and diagnosis. Curr Opin Infect Dis. 2007;20(3):284-292.

[56] Matsunaga J, Sanchez Y, Xu X, Haake DA. Osmolarity, a key environmental signal controlling expression of leptospiral proteins LigA and LigB and the extracellular release of LigA. Infect Immun. 2005;73(1):70-78.

[57] Vinetz JM. Leptospirosis. Curr Opin Infect Dis. 2001;14(5):527-538.

[58] Abela-Ridder B, Sikkema R, Hartskeerl RA. Estimating the burden of human leptospirosis. Int J Antimicrob Agents. 2010;36 Suppl 1:S5-7.

[59] Medeiros FR, Spichler A, Athanazio DA. Leptospirosis-associated disturbances of blood vessels, lungs and hemostasis. Acta Trop. 2010;115(1-2):155-162.

[60] Gomes-Solecki M, Santecchia I, Werts C. Animal models of leptospirosis: Of mice and hamsters. Front Immunol. 2017;8:58

[61] Fraga TR, Barbosa AS, Isaac L. Leptospirosis: aspects of innate immunity, immunopathogenesis and immune evasion from the complement system. Scand J Immunol. 2011;73(5):408-419.

[62] Schneider MC, Najera P, Aldighieri S, et al. Leptospirosis outbreaks in Nicaragua: identifying critical areas and exploring drivers for evidence-based planning. Int J Environ Res Public Health. 2012;9(11):3883-3910.

[63] Adler B, de la Peña Moctezuma A. Leptospira and leptospirosis. Vet Microbiol. 2010;140(3-4):287-296.

[64] Smythe LD, Smith IL, Smith GA, et al. A quantitative PCR (TaqMan) assay for pathogenic Leptospira spp. BMC Infect Dis. 2002;2:13.

[65] Goarant C, Laumond-Barny S, Perez J, et al. Outbreak of leptospirosis in New Caledonia: diagnosis issues and burden of disease. Trop Med Int Health. 2009;14(8):926-929.

[66] Levett PN, Morey RE, Galloway RL, et al. Detection of pathogenic leptospires by real-time quantitative PCR. J Med Microbiol. 2005;54(Pt 1):45-49.

[67] Nally JE, Fishbein MC, Blanco DR, Lovett MA. Lethal infection of C3H/HeJ and C3H/SCID mice with an isolate of Leptospira interrogans serovar copenhageni. Infect Immun. 2005;73(10):7014-7017.

[68] McBride AJ, Santos BL, Queiroz A, et al. Evaluation of four whole-cell Leptospira vaccines in hamsters. Vaccine. 2007;25(38):6589-6593.

[69] Yang HL, Jiang XC, Zhang XY, et al. Thrombocytopenia in the experimental leptospirosis of guinea pig is not related to disseminated intravascular coagulation. BMC Infect Dis. 2006;6:19.

[70] Bandara M, Ananda M, Wickramage K, et al. Globalization of leptospirosis through travel and migration. Global Health. 2014;10:61.

[71] Limmathurotsakul D, Turner EL, Wuthiekanun V, et al. Fool's gold: Why imperfect reference tests are undermining the evaluation of novel diagnostics: a reevaluation of 5 diagnostic tests for leptospirosis. Clin Infect Dis. 2012;55(3):322-331.

[72] Haake DA, Matsunaga J. Leptospira: a spirochaete with a hybrid outer membrane. Mol Microbiol. 2010;77(4):805-814.

[73] Stern EJ, Galloway R, Shadomy SV, et al. Outbreak of leptospirosis among Adventure Race participants in Florida, 2005. Clin Infect Dis. 2010;50(6):843-849.

[74] Chierakul W, Tientadakul P, Suputtamongkol Y, et al. Activation of the coagulation cascade in patients with leptospirosis. Clin Infect Dis. 2008;46(2):254-260.

[75] Toyokawa T, Ohnishi M, Koizumi N. Diagnosis of acute leptospirosis. Expert Rev Anti Infect Ther. 2011;9(1):111-121.

[76] Signorini ML, Lottersberger J, Tarabla HD, Vanasco NB. Enzyme-linked immunosorbent assay to diagnose human leptospirosis: a meta-analysis of the published literature. Epidemiol Infect. 2013;141(1):22-32.

[77] Chirathaworn C, Inwattana R, Poovorawan Y, Suwancharoen D. Interpretation of microscopic agglutination test for leptospirosis diagnosis and seroprevalence. Asian Pac J Trop Biomed. 2014;4(Suppl 1):S162-S164.

[78] Lau CL, Smythe LD, Craig SB, Weinstein P. Climate change, flooding, urbanisation and leptospirosis: fuelling the fire? Trans R Soc Trop Med Hyg. 2010;104(10):631-638.

[79] Desakorn V, Wuthiekanun V, Thanachartwet V, et al. Accuracy of a commercial IgM ELISA for the diagnosis of human leptospirosis in Thailand. Am J Trop Med Hyg. 2012;86(3):524-527.

[80] Picardeau M. Diagnosis and epidemiology of leptospirosis. Med Mal Infect. 2013;43(1):1-9.

[81] Grassmann AA, Souza JD, McBride AJ. A novel leptospiral protein increases ICAM-1 and E-selectin expression in human umbilical vein endothelial cells. FEMS Microbiol Lett. 2012;335(1):38-45.

[82] Musso D, La Scola B. Laboratory diagnosis of leptospirosis: a challenge. J Microbiol Immunol Infect. 2013;46(4):245-252.

[83] Evangelista KV, Coburn J. Leptospira as an emerging pathogen: a review of its biology, pathogenesis and host immune responses. Future Microbiol. 2010;5(9):1413-1425.

[84] Waggoner JJ, Pinsky BA. Molecular diagnostics for human leptospirosis. Curr Opin Infect Dis. 2016;29(5):440-445.

[85] Haake DA, Dundoo M, Cader R, et al. Leptospirosis, water sports, and chemoprophylaxis. Clin Infect Dis. 2002;34(9):e40-e43.

[86] Goris MG, Hartskeerl RA. Leptospirosis serodiagnosis by the microscopic agglutination test. Curr Protoc Microbiol. 2014;32:12E.5.1-12E.5.18.

[87] Ganoza CA, Matthias MA, Collins-Richards D, et al. Determining risk for severe leptospirosis by molecular analysis of environmental surface waters for pathogenic Leptospira. PLoS Med. 2006;3(8):e308.

[88] Céspedes M, Glenny M, Felices V, et al. Prueba de ELISA indirecta para la detección de anticuerpos IgM para el diagnóstico de leptospirosis humana. Rev Peru Med Exp Salud Publica. 2002;19(1):24-27.

[89] Levett PN, Branch SL. Evaluation of two enzyme-linked immunosorbent assay methods for detection of immunoglobulin M antibodies in acute leptospirosis. Am J Trop Med Hyg. 2002;66(6):745-748.

[90] Hartskeerl RA, Smits HL, Korver H, et al. International course on laboratory methods for the diagnosis of leptospirosis. Amsterdam: Royal Tropical Institute; 2006.

[91] Ratnam S. Leptospirosis: an Indian perspective. Indian J Med Microbiol. 1994;12(4):228-239.

[92] Gasem MH, Wagenaar JF, Goris MG, et al. Murine typhus and leptospirosis as causes of acute undifferentiated fever, Indonesia. Emerg Infect Dis. 2009;15(6):975-977.

[93] Dorigatti F, Agampodi SB, Matthias MA, et al. Clinical manifestations of leptospirosis among patients admitted to hospital in northeastern Malaysia. Trop Med Int Health. 2019;24(5):593-604.

[94] Daher EF, Lima RS, Silva Júnior GB, et al. Clinical presentation of leptospirosis: a retrospective study of 201 patients in a metropolitan city of Brazil. Braz J Infect Dis. 2010;14(1):3-10.

[95] Marotto PC, Nascimento CM, Eluf-Neto J, et al. Acute lung injury in leptospirosis: clinical and laboratory features, outcome, and factors associated with mortality. Clin Infect Dis. 1999;29(6):1561-1563.

[96] Levett PN, Branch SL, Edwards CN. Detection of dengue infection in patients investigated for leptospirosis in Barbados. Am J Trop Med Hyg. 2000;62(1):112-114.

[97] Spichler AS, Vilaça PJ, Athanazio DA, et al. Predictors of lethality in severe leptospirosis in urban Brazil. Am J Trop Med Hyg. 2008;79(6):911-914.

[98] Panaphut T, Domrongkitchaiporn S, Thinkamrop B. Prognostic factors of death in leptospirosis: a prospective cohort study in Khon Kaen, Thailand. Int J Infect Dis. 2002;6(1):52-59.

[99] Hochedez P, Theodose R, Olive C, et al. Factors associated with severe leptospirosis, Martinique, 2010-2013. Emerg Infect Dis. 2015;21(12):2221-2224.

[100] Gouveia EL, Metcalfe J, de Carvalho AL, et al. Leptospirosis-associated severe pulmonary hemorrhagic syndrome, Salvador, Brazil. Emerg Infect Dis. 2008;14(3):505-508.

[101] Rajapakse S, Rodrigo C, Haniffa R. Developing a clinically relevant classification to predict mortality in severe leptospirosis. J Emerg Trauma Shock. 2010;3(3):213-219.

[102] Mathew T, Satishchandra P, Mahadevan A, et al. Neuroleptospirosis - revisited: experience from a tertiary care neurological centre from south India. Indian J Med Res. 2006;124(2):155-162.

[103] Daher EF, Zanetta DM, Cavalcante MB, Abdulkader RC. Risk factors for death and changing patterns in leptospirosis acute renal failure. Am J Trop Med Hyg. 1999;61(4):630-634.

[104] Wagenaar JF, Goris MG, Partiningrum DL, et al. Coagulation disorders in patients with severe leptospirosis are associated with severe bleeding and mortality. Trop Med Int Health. 2010;15(2):152-159.

[105] Dupont H, Dupont-Perdrizet D, Perie JL, et al. Leptospirosis: prognostic factors associated with mortality. Clin Infect Dis. 1997;25(3):720-724.

[106] Weil A. Ueber eine eigenthümliche, mit Milztumor, Icterus und Nephritis einhergehende acute Infectionskrankheit. Dtsch Arch Klin Med. 1886;39:209-232.

[107] Trevejo RT, Rigau-Pérez JG, Ashford DA, et al. Epidemic leptospirosis associated with pulmonary hemorrhage-Nicaragua, 1995. J Infect Dis. 1998;178(5):1457-1463.

[108] Andrade L, de Francesco Daher E, Seguro AC. Leptospiral nephropathy. Semin Nephrol. 2008;28(4):383-394.

[109] Dolhnikoff M, Mauad T, Bethlem EP, Carvalho CR. Pathology and pathophysiology of pulmonary manifestations in leptospirosis. Braz J Infect Dis. 2007;11(1):142-148.

[110] Shah K, Amonkar GP, Kamat RN, Deshpande JR. Cardiac findings in leptospirosis. J Clin Pathol. 2010;63(2):119-123.

[111] Spichler A, Vilacá P, Athanazio D, et al. Predictors of lethality in severe leptospirosis in urban Brazil. Am J Trop Med Hyg. 2008;79(6):911-914.

[112] Ellis WA. Leptospirosis as a cause of reproductive failure. Vet Clin North Am Food Anim Pract. 1994;10(3):463-478.

[113] Grooms DL. Reproductive losses caused by bovine viral diarrhea virus and leptospirosis. Theriogenology. 2006;66(3):624-628.

[114] Thiermann AB. Leptospirosis: current developments and trends. J Am Vet Med Assoc. 1984;184(6):722-725.

[115] Leonard FC, Quinn PJ, Ellis WA, O'Farrell K. Duration of urinary excretion of leptospires by cattle naturally or experimentally infected with Leptospira interrogans serovar hardjo. Vet Rec. 1992;131(19):435-439.

[116] Bolin CA, Alt DP. Clinical signs, diagnosis, and prevention of bovine leptospirosis. Bovine Practitioner. 1999;33(1):50-55.

[117] Dhaliwal GS, Murray RD, Ellis WA. Reproductive performance of dairy herds infected with Leptospira interrogans serovar hardjo relative to the year of diagnosis. Vet Rec. 1996;138(12):272-276.

[118] Ellis WA, O'Brien JJ, Neill SD, et al. Bovine leptospirosis: serological findings in aborting cows. Vet Rec. 1982;110(8):178-180.

[119] Lilenbaum W, Varges R, Brandão FZ, et al. Detection of Leptospira spp. in semen and vaginal fluids of goats and sheep by polymerase chain reaction. Theriogenology. 2008;69(7):837-842.

[120] Cortese VS, Behan S, Galvin JE, et al. Evaluation of two antimicrobial therapies in the treatment of Leptospira borgpetersenii serovar hardjo infection in beef cattle. Am J Vet Res. 2007;68(9):984-989.

[121] Alt DP, Zuerner RL, Bolin CA. Evaluation of antibiotics for treatment of cattle infected with Leptospira borgpetersenii serovar hardjo. J Am Vet Med Assoc. 2001;219(5):636-639.

[122] Ko AI, Galvão Reis M, Ribeiro Dourado CM, et al. Urban epidemic of severe leptospirosis in Brazil. Lancet. 1999;354(9181):820-825.

[123] Rajapakse S, Rodrigo C, Balaji K, Fernando SD. Atypical manifestations of leptospirosis. Trans R Soc Trop Med Hyg. 2015;109(5):294-302.

[124] Lau C, Smythe L, Weinstein P. Leptospirosis: an emerging disease in travellers. Travel Med Infect Dis. 2010;8(1):33-39.

[125] Carles G, Montoya E, Joly F, Peneau C. Leptospirosis and pregnancy. Eleven cases in French Guiana. J Gynecol Obstet Biol Reprod (Paris). 1995;24(4):418-421.

[126] Katz AR, Ansdell VE, Effler PV, et al. Assessment of the clinical presentation and treatment of 353 cases of laboratory-confirmed leptospirosis in Hawaii, 1974-1998. Clin Infect Dis. 2001;33(11):1834-1841.

[127] Sharma KK, Kalawat U. Early diagnosis of leptospirosis by conventional methods: one-year prospective study. Indian J Pathol Microbiol. 2008;51(2):209-211.

[128] Terpstra WJ, Ligthart GS, Schoone GJ. ELISA for the detection of specific IgM and IgG in human leptospirosis. J Gen Microbiol. 1985;131(2):377-385.

[129] Levett PN, Branch SL, Whittington CU, et al. Two methods for rapid serological diagnosis of acute leptospirosis. Clin Diagn Lab Immunol. 2001;8(2):349-351.

[130] Bharti AR, Nally JE, Ricaldi JN, et al. Leptospirosis: a zoonotic disease of global importance. Lancet Infect Dis. 2003;3(12):757-771.

[131] Picardeau M, Bertherat E, Jancloes M, et al. Rapid tests for diagnosis of leptospirosis: current tools and emerging technologies. Diagn Microbiol Infect Dis. 2014;78(1):1-8.

[132] Vijayachari P, Sugunan AP, Shriram AN. Leptospirosis: an emerging global public health problem. J Biosci. 2008;33(4):557-569.

[133] Smythe LD, Smith IL, Smith GA, et al. A quantitative PCR (TaqMan) assay for pathogenic Leptospira spp. BMC Infect Dis. 2002;2:13.

[134] Faine S. Guidelines for the control of leptospirosis. WHO offset publication No. 67. Geneva: World Health Organization; 1982.

[135] Hartskeerl RA, Collares-Pereira M, Ellis WA. Emergence, control and re-emerging leptospirosis: dynamics of infection in the changing world. Clin Microbiol Infect. 2011;17(4):494-501

[136] Haake DA, Levett PN. Leptospirosis: a neglected disease? Clinical Microbiology Newsletter. 2012;34(11):87-92.

[137] Cinco M. New insights into the pathogenicity of leptospires: evasion of host defences. New Microbiol. 2010;33(4):283-292.

[138] Levett PN, Morey RE, Galloway RL, Steigerwalt AG. Leptospira broomii sp. nov., isolated from humans with leptospirosis. Int J Syst Evol Microbiol. 2006;56(3):671-673.

[139] Adler B, Faine S. The antibodies involved in the human immune response to leptospiral infection. J Med Microbiol. 1978;11(4):387-400.

[140] Matthias MA, Levett PN. Leptospiral carriage by mice and mongooses on the island of Barbados. West Indian Med J. 2002;51(1):10-13.

[141] Cumberland P, Everard CO, Levett PN. Assessment of the efficacy of an IgM-ELISA and microscopic agglutination test (MAT) in the diagnosis of acute leptospirosis. Am J Trop Med Hyg. 1999;61(5):731-734.

[142] Bajani MD, Ashford DA, Bragg SL, et al. Evaluation of four commercially available rapid serologic tests for diagnosis of leptospirosis. J Clin Microbiol. 2003;41(2):803-809.

[143] Goris MG, Leeflang MM, Boer KR, et al. Establishment of valid laboratory case definition for human leptospirosis. J Bacteriol Parasitol. 2012;3:132.

[144] Merien F, Portnoi D, Bourhy P, et al. A rapid and quantitative method for the detection of Leptospira species in human leptospirosis. FEMS Microbiol Lett. 2005;249(1):139-147.

[145] Stoddard RA, Gee JE, Wilkins PP, et al. Detection of pathogenic Leptospira spp. through TaqMan polymerase chain reaction targeting the LipL32 gene. Diagn Microbiol Infect Dis. 2009;64(3):247-255.

[146] Ahmed A, Engelberts MF, Boer KR, et al. Development and validation of a real-time PCR for detection of pathogenic Leptospira species in clinical materials. PLoS One. 2009;4(9):e7093.

[147] Johnson RC, Harris VG. Differentiation of pathogenic and saprophytic leptospires. I. Growth at low temperatures. J Bacteriol. 1967;94(1):27-31.

[148] Ellinghausen HC Jr, McCullough WG. Nutrition of Leptospira pomona and growth of 13 other serotypes: fractionation of oleic albumin complex and a medium of bovine albumin and polysorbate 80. Am J Vet Res. 1965;26:45-51.

[149] Palmer MF, Zochowski WJ. Survival of leptospires in commercial blood culture systems revisited. J Clin Pathol. 2000;53(9):713-714.

[150] Ellis WA. Control of canine leptospirosis in Europe: time for a change? Vet Rec. 2010;167(16):602-605.

[151] Schönberg A, Reichel U, Geiger R. IgM and IgG antibody response in cattle experimentally infected with Leptospira interrogans serovar hardjo. Zentralbl Veterinarmed B. 1988;35(3):203-212.

[152] Boqvist S, Eliasson-Selling L, Bergström K, Magnusson U. The association between rainfall and seropositivity to Leptospira in outdoor reared pigs. Vet J. 2012;193(1):135-139.

[153] Bolin CA, Cassells JA, Zuerner RL, Trueba G. Effect of vaccination with a monovalent Leptospira interrogans serovar hardjo type hardjo-bovis vaccine on type hardjo-bovis infection of cattle. Am J Vet Res. 1991;52(10):1639-1643.

[154] Smith CR, Ketterer PJ, McGowan MR, Corney BG. A review of laboratory techniques and their use in the diagnosis of Leptospira interrogans serovar hardjo infection in cattle. Aust Vet J. 1994;71(9):290-294.

[155] Thiermann AB. The Norway rat as a selective chronic carrier of Leptospira icterohaemorrhagiae. J Wildl Dis. 1981;17(1):39-43.

[156] Nally JE, Mullen W, Callanan JJ, et al. Detection of urinary biomarkers in reservoir hosts of leptospirosis. PLoS One. 2014;9(3):e93209.

[157] Picardeau M. Genomics, proteomics, and genetics of leptospira. Curr Top Microbiol Immunol. 2015;387:43-63.

[158] Cerqueira GM, McBride AJ, Picardeau M, et al. Distribution of the leptospiral immunoglobulin-like (lig) genes in pathogenic Leptospira species and application of ligB to typing leptospiral isolates. J Med Microbiol. 2009;58(Pt 9):1173-1181.

[159] Papa A, Theoharidou D, Antoniadis A. Pulmonary involvement and leptospirosis, Greece. Emerg Infect Dis. 2009;15(5):834-835.

[160] De Silva NL, Niloofa M, Fernando N, et al. Changes in full blood count parameters in leptospirosis: a prospective study. Int Arch Med. 2014;7:31.

[161] Naing C, Reid SA, Aye SN, et al. Risk factors for human leptospirosis following flooding: a meta-analysis of observational studies. PLoS One. 2019;14(5):e0217643.

[162] Vinetz JM, Glass GE, Flexner CE, et al. Sporadic urban leptospirosis. Ann Intern Med. 1996;125(10):794-798.

[163] Suputtamongkol Y, Pongtavornpinyo W, Lubell Y, et al. Strategies for diagnosis and treatment of suspected leptospirosis: a cost-benefit analysis. PLoS Negl Trop Dis. 2010;4(2):e610.

[164] Brett-Major DM, Lipnick RJ. Antibiotic prophylaxis for leptospirosis. Cochrane Database Syst Rev. 2009;(3):CD007342.

[165] Watt G, Padre LP, Tuazon ML, et al. Placebo-controlled trial of intravenous penicillin for severe and late leptospirosis. Lancet. 1988;1(8583):433-435.

[166] Edwards CN, Nicholson GD, Hassell TA, et al. Penicillin therapy in icteric leptospirosis. Am J Trop Med Hyg. 1988;39(4):388-390.

[167] Panaphut T, Domrongkitchaiporn S, Vibhagool A, et al. Ceftriaxone compared with sodium penicillin G for treatment of severe leptospirosis. Clin Infect Dis. 2003;36(12):1507-1513.

[168] Costa E, Lopes AA, Sacramento E, et al. Penicillin at the late stage of leptospirosis: a randomized controlled trial. Rev Inst Med Trop Sao Paulo. 2003;45(3):141-145.

[169] Griffith ME, Hospenthal DR, Murray CK. Antimicrobial therapy of leptospirosis. Curr Opin Infect Dis. 2006;19(6):533-537.

[170] Phimda K, Hoontrakul S, Suttinont C, et al. Doxycycline versus azithromycin for treatment of leptospirosis and scrub typhus. Antimicrob Agents Chemother. 2007;51(9):3259-3263.

[171] Andrade L, Cleto S, Seguro AC. Door-to-dialysis time and daily hemodialysis in patients with leptospirosis: impact on mortality. Clin J Am Soc Nephrol. 2007;2(4):739-744.

[172] Cerqueira TB, Athanazio DA, Spichler AS, Seguro AC. Renal involvement in leptospirosis--new insights into pathophysiology and treatment. Braz J Infect Dis. 2008;12(3):248-252.

[173] Chawla V, Trivedi TH, Yeolekar ME. Epidemic of leptospirosis: an ICU experience. J Assoc Physicians India. 2004;52:619-622.

[174] Paganin F, Bourdin A, Dalban C, et al. Leptospirosis in Reunion Island (Indian Ocean): analysis of factors associated with severity in 147 confirmed cases. Intensive Care Med. 2007;33(11):1959-1966.

[175] Marotto PC, Ko AI, Murta-Nascimento C, et al. Early identification of leptospirosis-associated pulmonary hemorrhage syndrome by use of a validated prediction model. J Infect. 2010;60(3):218-223.

[176] Helmerhorst HJ, van Tol EN, Tuinman PR, et al. Severe pulmonary manifestation of leptospirosis. Neth J Med. 2012;70(5):215-221.

[177] Carles G, Montoya E, Joly F, Peneau C. Leptospirosis and pregnancy. Eleven cases in French Guiana. J Gynecol Obstet Biol Reprod (Paris). 1995;24(4):418-421.

[178] McGready R, Ashley EA, Wuthiekanun V, et al. Arthropod borne disease: the leading cause of fever in pregnancy on the Thai-Burmese border. PLoS Negl Trop Dis. 2010;4(11):e888.

[179] Shaked Y, Shpilberg O, Samra D, Samra Y. Leptospirosis in pregnancy and its effect on the fetus: case report and review. Clin Infect Dis. 1993;17(2):241-243.

[180] Colt S, Pavlin BI, Kool JL, et al. Human leptospirosis in The Federated States of Micronesia: a hospital-based febrile illness survey. BMC Infect Dis. 2014;14:186

[181] Cruz LS, Vargas R, Lopes AA. Leptospirosis: a worldwide resurgent zoonosis and important cause of acute renal failure and death in developing nations. Ethn Dis. 2009;19(1 Suppl 1):S1-37-41.

[182] Tubiana S, Mikulski M, Becam J, et al. Risk factors and predictors of severe leptospirosis in New Caledonia. PLoS Negl Trop Dis. 2013;7(1):e1991.

[183] Alt DP, Bolin CA. Preliminary evaluation of antimicrobial agents for treatment of Leptospira interrogans serovar pomona infection in hamsters and swine. Am J Vet Res. 1996;57(1):59-62.

[184] Smith CR, Corney BG, McGowan MR, et al. Amoxicillin as an alternative to dihydrostreptomycin sulphate for treating cattle infected with Leptospira borgpetersenii serovar hardjo. Aust Vet J. 1997;75(11):818-821.

[185] Bolin CA. Diagnosis of leptospirosis: a reemerging disease of companion animals. Semin Vet Med Surg (Small Anim). 1996;11(3):166-171.

[186] Ellis WA. Bovine leptospirosis in the tropics: prevalence, pathogenesis and control. Prev Vet Med. 1984;2(1-4):411-421.

[187] Bolin CA, Alt DP. Use of a monovalent leptospiral vaccine to prevent renal colonization and urinary shedding in cattle exposed to Leptospira borgpetersenii serovar hardjo. Am J Vet Res. 2001;62(7):995-1000.

[188] Lilenbaum W, Souza GN. Factors associated with bovine leptospirosis in Rio de Janeiro, Brazil. Res Vet Sci. 2003;75(3):249-251.

[189] Phraisuwan P, Whitney EA, Tharmaphornpilas P, et al. Leptospirosis: skin wounds and control strategies, Thailand, 1999. Emerg Infect Dis. 2002;8(12):1455-1459.

[190] Dreyfus A, Benschop J, Collins-Emerson J, et al. Leptospira seroprevalence and risk factors in meat workers in New Zealand. Int J Environ Res Public Health. 2014;11(2):1756-1775.

[191] Sharma S, Vijayachari P, Sugunan AP, et al. Seroprevalence of leptospirosis among high-risk population of Andaman Islands, India. Am J Trop Med Hyg. 2006;74(2):278-283.

[192] Reis RB, Ribeiro GS, Felzemburgh RD, et al. Impact of environment and social gradient on Leptospira infection in urban slums. PLoS Negl Trop Dis. 2008;2(4):e228.

[193] Sarkar U, Nascimento SF, Barbosa R, et al. Population-based case-control investigation of risk factors for leptospirosis during an urban epidemic. Am J Trop Med Hyg. 2002;66(5):605-610.

[194] Lau CL, Watson CH, Lowry JH, et al. Human leptospirosis infection in Fiji: an eco-epidemiological approach to identifying risk factors and environmental drivers for transmission. PLoS Negl Trop Dis. 2016;10(1):e0004405.

[195] Takafuji ET, Kirkpatrick JW, Miller RN, et al. An efficacy trial of doxycycline chemoprophylaxis against leptospirosis. N Engl J Med. 1984;310(8):497-500.

[196] Sehgal SC, Sugunan AP, Murhekar MV, et al. Randomized controlled trial of doxycycline prophylaxis against leptospirosis in an endemic area. Int J Antimicrob Agents. 2000;13(4):249-255.

[197] Brett-Major DM, Lipnick RJ. Antibiotic prophylaxis for leptospirosis. Cochrane Database Syst Rev. 2009;(3):CD007342.

[198] Little TW, Hathaway SC, Boughton ES, et al. Development of a control strategy for Leptospira hardjo infection in a closed beef herd. Vet Rec. 1992;131(17):383-386.

[199] Marshall RB, Broughton ES, Hellstrom JS. Protection of cattle against natural challenge with Leptospira interrogans serovar hardjo using a hardjo-pomona vaccine. N Z Vet J. 1979;27(6):114-116.

[200] Bolin CA, Zuerner RL, Trueba G. Effect of vaccination with a pentavalent leptospiral vaccine containing Leptospira interrogans serovar hardjo type hardjo-bovis on type hardjo-bovis infection of cattle. Am J Vet Res. 1989;50(12):2004-2008.

[201] Ellis WA. Leptospirosis as a cause of reproductive failure. Vet Clin North Am Food Anim Pract. 1994;10(3):463-478.

[202] Subharat S, Wilson PR, Heuer C, Collins-Emerson JM. Vaccination for leptospirosis improved the weaning percentage of 2-year-old farmed red deer hinds in New Zealand. N Z Vet J. 2011;59(4):191-196.

[203] Adler B. Vaccines against leptospirosis. Curr Top Microbiol Immunol. 2015;387:251-272.

[204] Ko AI, Goarant C, Picardeau M. Leptospira: the dawn of the molecular genetics era for an emerging zoonotic pathogen. Nat Rev Microbiol. 2009;7(10):736-747.

[205] Hartskeerl RA, Collares-Pereira M, Ellis WA. Emergence, control and re-emerging leptospirosis: dynamics of infection in the changing world. Clin Microbiol Infect. 2011;17(4):494-501.

[206] Mwachui MA, Crump L, Hartskeerl R, et al. Environmental and behavioural determinants of leptospirosis transmission: a systematic review. PLoS Negl Trop Dis. 2015;9(9):e0003843.

[207] Goarant C. Leptospirosis: risk factors and management challenges in developing countries. Res Rep Trop Med. 2016;7:49-62.

[208] Zinsstag J, Schelling E, Waltner-Toews D, Tanner M. From "one medicine" to "one health" and systemic approaches to health and well-being. Prev Vet Med. 2011;101(3-4):148-156.

[209] Schneider MC, Jancloes M, Buss DF, et al. Leptospirosis: a silent epidemic disease. Int J Environ Res Public Health. 2013;10(12):7229-7234.

[210] Lau CL, Smythe LD, Craig SB, Weinstein P. Climate change, flooding, urbanisation and leptospirosis: fuelling the fire? Trans R Soc Trop Med Hyg. 2010;104(10):631-638

[211] Mohan ARM, Cumberbatch A, Adesiyun AA, Chadee DD. Epidemiology of human leptospirosis in Trinidad and Tobago, 1996-2007: a retrospective study. Acta Trop. 2009;112(3):260-265.

[212] Cachay ER, Vinetz JM. A global research agenda for leptospirosis. J Postgrad Med. 2005;51(3):174-178.

[213] Pappas G, Cascio A. Optimal treatment of leptospirosis: queries and projections. Int J Antimicrob Agents. 2006;28(6):491-496.

[214] Slack A. Leptospirosis. Aust Fam Physician. 2010;39(7):495-498.

[215] Victoriano AF, Smythe LD, Gloriani-Barzaga N, et al. Leptospirosis in the Asia Pacific region. BMC Infect Dis. 2009;9:147.

[216] Levett PN, Haake DA. Leptospira species (leptospirosis). In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 8th ed. Philadelphia, PA: Elsevier Saunders; 2015:2714-2720.

[217] Bharti AR, Nally JE, Ricaldi JN, et al. Leptospirosis: a zoonotic disease of global importance. Lancet Infect Dis. 2003;3(12):757-771.

[218] Ganoza CA, Matthias MA, Collins-Richards D, et al. Determining risk for severe leptospirosis by molecular analysis of environmental surface waters for pathogenic Leptospira. PLoS Med. 2006;3(8):e308.

[219] Lau CL, Smythe LD, Craig SB, Weinstein P. Climate change, flooding, urbanisation and leptospirosis: fuelling the fire? Trans R Soc Trop Med Hyg. 2010;104(10):631-638.

[220] McBride AJ, Athanazio DA, Reis MG, Ko AI. Leptospirosis. Curr Opin Infect Dis. 2005;18(5):376-386